VG101 Phase I/II to Treat Vulvar and Vaginal Atrophy in Post-Menopausal Women

Summary

To conduct a prospective, randomized, blinded, placebo controlled, dose escalation clinical trial in 4 cohorts of 10 postmenopausal women (total N=40) aged 45 to 65 years with at least one menopausal vaginal symptom, vaginal pH \> 5.0 and \> 20% parabasal vaginal epithelial cells.

Timeline

Start

2012-06

Primary completion

2013-06

Completion

2013-08

Drugs

Indications